ATP6V1F

Across TCGA pan-cancer cohorts, ATP6V1F mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP6V1F data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP6V1F mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATP6V1F expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where ATP6V1F mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.850	0.449	.007	42	view →
COAD	DFS	Median	All	0.917	1.000	.011	30	view →
HNSC	OS	Median	IV	0.851	0.600	.013	20	view →
PDAC	OS	Tertile	IV	0.231	0.916	.024	6	view →
UCEC	DFS	Median	All	0.783	0.910	.046	2	view →
LSCC	DFS	Tertile	All	0.876	0.676	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP6V1F–CCRCC (DFS)

Open the CCRCC breakdown →